Popular Articles

New Study Results Verify That PNH Cells Are Found In Majority Of Patients With Bone Marrow Failure Syndromes
Paroxysmal nocturnal hemoglobinuria (PNH) cells are present in the majority of patients with myelodysplastic syndromes (MDS), aplastic anemia (AA), and other bone marrow failure syndromes (BMF), according to interim results from 5,285 patients enrolled in the EXPLORE trial. EXPLORE (EXamination of PNH, by Level Of CD59 on REd and white blood cells) is the first large multicenter study to determine the frequency of PNH cells in these patient populations using a central laboratory conducting a high sensitivity test for PNH cells. The findings from EXPLORE will be presented tomorrow at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). The EXPLORE trial was sponsored by Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN).
buy viagra
A Woman's Partner Status Found To Be Relevant For Her Interest In The Opposite Sex
A study by neuroscientist Heather Rupp and her team found that a woman"s partner status influenced her interest in the opposite sex. In the studyÂð, published in the March issue of Human Nature, women both with and without sexual partners showed little difference in their subjective ratings of photos of men when considering such measures as masculinity and attractiveness. However, the women who did not have sexual partners spent more time evaluating photos of men, demonstrating a greater interest in the photos. No such difference was found between men who had sexual partners and those who did not.
News of the day
Schering-Plough Expands Vicriviroc Phase II Study In Treatment-Naive Patients With HIV
Schering-Plough Corporation (NYSE: SGP) announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment.
Medical Devices

Successful Initial Safety Tests For Genetically-modified Rice That Fights Allergy - Journal Of Agricultural And Food Chemistry

In a first-of-its-kind advance toward the next generation of genetically modified foods - intended to improve consumers" health - researchers in Japan are reporting that a new transgenic rice designed to fight a common pollen allergy appears safe in animal studies. Their report is in the current issue of ACS" Journal of Agricultural and Food Chemistry, a bi-weekly publication. Fumio Takaiwa and colleagues note that the first generation of genetically-modified crops was designed to help keep crops weed and insect free. The next generation of transgenic crops is being developed to directly benefit human health. This includes veggies and grains that produce higher levels of nutrients, such as vitamins and minerals, or even medicines and vaccines. Like the first generation of transgenic foods, however, researchers are anxiously trying to determine whether foods produced from these "biopharmaceutical" crops will be safe for humans and the environment. The scientists describe development of a transgenic rice plant that has been genetically- engineered to fight allergies to Japanese cedar pollen, a growing public health problem in Japan that affects about 20 percent of the population. In laboratory studies, the researchers fed a steamed version of the transgenic rice and a non-transgenic version to a group of monkeys everyday for 26 weeks. At the end of the study period, the test animals did not show any health problems, in an initial demonstration that the allergy-fighting rice may be safe for consumption, the researchers say. "26-Week Oral Safety Study in macaques for Transgenic Rice Containing major Human T-Cell Epitope Peptides from Japanese Cedar Pollen Allergens" American Chemical Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):